Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 6/20 | 0.35 |
| ▸ | THRA | P10827 | 5/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452375 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2CD69ELANEPTGDR2CYP2C19 | |
| SCHEMBL3451283 | 0.80 | SMN1; SMN2 (0.38) | SMN1; SMN2CYP2C19KMT2A | |
| SCHEMBL3452453 | 0.77 | THRB (0.40) | SMN1; SMN2CD69ELANETHRBTHRA | |
| SCHEMBL3452046 | 0.77 | RORC (0.37) | — | |
| SCHEMBL2192769 | 0.75 | ALDH1A1 (0.40) | SMN1; SMN2CYP2C19KMT2APPARG | |
| SCHEMBL3453686 | 0.73 | ALDH1A1 (0.47) | SMN1; SMN2CYP2C19KMT2A | |
| SCHEMBL3457282 | 0.72 | ALDH1A1 (0.46) | CYP2C19KMT2A | |
| SCHEMBL3452486 | 0.72 | THRA (0.38) | SMN1; SMN2CD69ELANECYP2C19THRB | |
| SCHEMBL2192012 | 0.71 | THRA (0.38) | SMN1; SMN2CD69ELANECYP2C19THRB | |
| SCHEMBL3452989 | 0.71 | RORC (0.52) | SMN1; SMN2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858819-B2 | Tris(formylphenyl) and novel polynuclear phenol derived therefrom | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | AS3MT, RRM2, SHROOM3 | SMN1; SMN2 2165/4885CD69 39/4885ELANE 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.